These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030 [TBL] [Abstract][Full Text] [Related]
3. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Masui T; Sakano S; Hasegawa Y; Warashina H; Ishiguro N Biomaterials; 2005 May; 26(14):1695-702. PubMed ID: 15576143 [TBL] [Abstract][Full Text] [Related]
4. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. Anandarajah AP; Schwarz EM J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334 [TBL] [Abstract][Full Text] [Related]
5. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602 [TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Gehrke T; Sers C; Morawietz L; Fernahl G; Neidel J; Frommelt L; Krenn V Scand J Rheumatol; 2003; 32(5):287-94. PubMed ID: 14690142 [TBL] [Abstract][Full Text] [Related]
7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602 [TBL] [Abstract][Full Text] [Related]
8. The OPG/RANKL/RANK system in metabolic bone diseases. Hofbauer LC; Kühne CA; Viereck V J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494 [TBL] [Abstract][Full Text] [Related]
9. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054 [TBL] [Abstract][Full Text] [Related]
10. Heritable disorders of the RANKL/OPG/RANK signaling pathway. Whyte MP; Mumm S J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):254-67. PubMed ID: 15615493 [TBL] [Abstract][Full Text] [Related]
11. RANKL-RANK signaling in osteoclastogenesis and bone disease. Wada T; Nakashima T; Hiroshi N; Penninger JM Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770 [TBL] [Abstract][Full Text] [Related]
12. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. Lu HK; Chen YL; Chang HC; Li CL; Kuo MY J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732 [TBL] [Abstract][Full Text] [Related]
13. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750 [TBL] [Abstract][Full Text] [Related]
14. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469 [TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158 [TBL] [Abstract][Full Text] [Related]
16. [Clinical implications of new insights into the regulation of bone resorption]. Lems WF; Bijlsma JW Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110 [TBL] [Abstract][Full Text] [Related]
17. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421 [TBL] [Abstract][Full Text] [Related]
18. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166 [TBL] [Abstract][Full Text] [Related]
19. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014 [TBL] [Abstract][Full Text] [Related]
20. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]